The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Encouraging early detection and breaking the silence around men’s health
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
We are taking Ayurveda to the world as a sustainable healthcare solution: Union Minister Prataprao Jadhav
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
The company has received approval from DCGI to begin patient enrolment and dosing in the country
The U.S. FDA issued a Form 483 with five observations
Subscribe To Our Newsletter & Stay Updated
